FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124720149> ?p ?o ?g. }

• W2124720149 endingPage "406" @default.
• W2124720149 startingPage "399" @default.
• W2124720149 abstract "Background— This is the primary report of the large-scale evaluation of lotrafiban, an orally administered IIb/IIIa receptor antagonist, a unique trial with respect to the platelet antagonist, protocol design, and inclusion of cerebrovascular disease in a significant proportion of patients. Methods and Results— Patients with vascular disease were randomized to lotrafiban 30 or 50 mg BID on the basis of age and predicted creatinine clearance or placebo in addition to aspirin at a dose ranging from 75 to 325 mg/d at the discretion of the physician-investigator. Follow-up was for up to 2 years. The primary end point was the composite of all-cause mortality, myocardial infarction, stroke, recurrent ischemia requiring hospitalization, and urgent revascularization. Of 9190 patients enrolled from 23 countries and 690 hospitals, 41% had cerebrovascular disease at the time of entry, and 59% had coronary artery disease. Death occurred in 2.3% of placebo-assigned patients and 3.0% of lotrafiban-group patients (hazard ratio 1.33, 95% CI 1.03 to 1.72, P =0.026), and the cause of excess death was vascular related. There was no significant difference in the primary end point (17.5% compared with 16.4%, respectively; hazard ratio 0.94, 95% CI 0.85 to 1.03, P =0.19). Serious bleeding was more frequent in the lotrafiban group (8.0% compared with 2.8%; P <0.001). Serious bleeding was more common among patients who received higher doses of aspirin (>162 mg/d), with or without lotrafiban. Conclusions— Lotrafiban, an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% increase in death rate, which was vascular in origin and not affected by the type of atherosclerotic involvement at entry to the trial. Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy." @default.
• W2124720149 created "2016-06-24" @default.
• W2124720149 creator A5013409359 @default.
• W2124720149 creator A5021525953 @default.
• W2124720149 creator A5023091399 @default.
• W2124720149 creator A5029768994 @default.
• W2124720149 creator A5039358787 @default.
• W2124720149 creator A5044212481 @default.
• W2124720149 creator A5045515686 @default.
• W2124720149 creator A5048833016 @default.
• W2124720149 creator A5050507154 @default.
• W2124720149 creator A5060370891 @default.
• W2124720149 creator A5060829829 @default.
• W2124720149 creator A5062439565 @default.
• W2124720149 creator A5063851108 @default.
• W2124720149 creator A5068943085 @default.
• W2124720149 creator A5069890731 @default.
• W2124720149 creator A5085360484 @default.
• W2124720149 creator A5089031635 @default.
• W2124720149 creator A5090092755 @default.
• W2124720149 creator A5090147492 @default.
• W2124720149 date "2003-07-29" @default.
• W2124720149 modified "2023-10-03" @default.
• W2124720149 title "Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease" @default.
• W2124720149 cites W1512461647 @default.
• W2124720149 cites W1989381306 @default.
• W2124720149 cites W2019472123 @default.
• W2124720149 cites W2025510606 @default.
• W2124720149 cites W2088434328 @default.
• W2124720149 cites W2329622594 @default.
• W2124720149 cites W2523247802 @default.
• W2124720149 cites W3016233686 @default.
• W2124720149 doi "https://doi.org/10.1161/01.cir.0000084501.48570.f6" @default.
• W2124720149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12874182" @default.
• W2124720149 hasPublicationYear "2003" @default.
• W2124720149 type Work @default.
• W2124720149 sameAs 2124720149 @default.
• W2124720149 citedByCount "177" @default.
• W2124720149 countsByYear W21247201492012 @default.
• W2124720149 countsByYear W21247201492013 @default.
• W2124720149 countsByYear W21247201492014 @default.
• W2124720149 countsByYear W21247201492015 @default.
• W2124720149 countsByYear W21247201492016 @default.
• W2124720149 countsByYear W21247201492017 @default.
• W2124720149 countsByYear W21247201492018 @default.
• W2124720149 countsByYear W21247201492019 @default.
• W2124720149 countsByYear W21247201492021 @default.
• W2124720149 countsByYear W21247201492022 @default.
• W2124720149 countsByYear W21247201492023 @default.
• W2124720149 crossrefType "journal-article" @default.
• W2124720149 hasAuthorship W2124720149A5013409359 @default.
• W2124720149 hasAuthorship W2124720149A5021525953 @default.
• W2124720149 hasAuthorship W2124720149A5023091399 @default.
• W2124720149 hasAuthorship W2124720149A5029768994 @default.
• W2124720149 hasAuthorship W2124720149A5039358787 @default.
• W2124720149 hasAuthorship W2124720149A5044212481 @default.
• W2124720149 hasAuthorship W2124720149A5045515686 @default.
• W2124720149 hasAuthorship W2124720149A5048833016 @default.
• W2124720149 hasAuthorship W2124720149A5050507154 @default.
• W2124720149 hasAuthorship W2124720149A5060370891 @default.
• W2124720149 hasAuthorship W2124720149A5060829829 @default.
• W2124720149 hasAuthorship W2124720149A5062439565 @default.
• W2124720149 hasAuthorship W2124720149A5063851108 @default.
• W2124720149 hasAuthorship W2124720149A5068943085 @default.
• W2124720149 hasAuthorship W2124720149A5069890731 @default.
• W2124720149 hasAuthorship W2124720149A5085360484 @default.
• W2124720149 hasAuthorship W2124720149A5089031635 @default.
• W2124720149 hasAuthorship W2124720149A5090092755 @default.
• W2124720149 hasAuthorship W2124720149A5090147492 @default.
• W2124720149 hasBestOaLocation W21247201491 @default.
• W2124720149 hasConcept C126322002 @default.
• W2124720149 hasConcept C127413603 @default.
• W2124720149 hasConcept C141071460 @default.
• W2124720149 hasConcept C142724271 @default.
• W2124720149 hasConcept C168563851 @default.
• W2124720149 hasConcept C203092338 @default.
• W2124720149 hasConcept C204787440 @default.
• W2124720149 hasConcept C207103383 @default.
• W2124720149 hasConcept C27081682 @default.
• W2124720149 hasConcept C2777628954 @default.
• W2124720149 hasConcept C2778213512 @default.
• W2124720149 hasConcept C2780645631 @default.
• W2124720149 hasConcept C44249647 @default.
• W2124720149 hasConcept C500558357 @default.
• W2124720149 hasConcept C71924100 @default.
• W2124720149 hasConcept C78519656 @default.
• W2124720149 hasConceptScore W2124720149C126322002 @default.
• W2124720149 hasConceptScore W2124720149C127413603 @default.
• W2124720149 hasConceptScore W2124720149C141071460 @default.
• W2124720149 hasConceptScore W2124720149C142724271 @default.
• W2124720149 hasConceptScore W2124720149C168563851 @default.
• W2124720149 hasConceptScore W2124720149C203092338 @default.
• W2124720149 hasConceptScore W2124720149C204787440 @default.
• W2124720149 hasConceptScore W2124720149C207103383 @default.
• W2124720149 hasConceptScore W2124720149C27081682 @default.
• W2124720149 hasConceptScore W2124720149C2777628954 @default.
• W2124720149 hasConceptScore W2124720149C2778213512 @default.
• W2124720149 hasConceptScore W2124720149C2780645631 @default.

• next